484 related articles for article (PubMed ID: 16029810)
21. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
[TBL] [Abstract][Full Text] [Related]
22. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
23. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
24. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
25. Decorin suppresses tumor cell-mediated angiogenesis.
Grant DS; Yenisey C; Rose RW; Tootell M; Santra M; Iozzo RV
Oncogene; 2002 Jul; 21(31):4765-77. PubMed ID: 12101415
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
27. The role of laminin-1 in the modulation of radiation damage in endothelial cells and differentiation.
Rose RW; Grant DS; O'Hara MD; Williamson SK
Radiat Res; 1999 Jul; 152(1):14-28. PubMed ID: 10381837
[TBL] [Abstract][Full Text] [Related]
28. Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors.
Fenton BM; Paoni SF; Ding I
Cancer Res; 2004 Aug; 64(16):5712-9. PubMed ID: 15313911
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
30. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
[TBL] [Abstract][Full Text] [Related]
31. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Harada K; Supriatno ; Yoshida H; Sato M
Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
[TBL] [Abstract][Full Text] [Related]
32. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.
Meissner M; Reichenbach G; Stein M; Hrgovic I; Kaufmann R; Gille J
Cancer Res; 2009 Mar; 69(5):1976-84. PubMed ID: 19223539
[TBL] [Abstract][Full Text] [Related]
34. Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body.
Coronella J; Li L; Johnson K; Pirie-Shepherd S; Roxas G; Levin N
Anticancer Res; 2009 Jun; 29(6):2243-52. PubMed ID: 19528489
[TBL] [Abstract][Full Text] [Related]
35. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
[TBL] [Abstract][Full Text] [Related]
37. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.
Zhao QT; Yue SQ; Cui Z; Wang Q; Cui X; Zhai HH; Zhang LH; Dou KF
Life Sci; 2007 Jan; 80(5):484-92. PubMed ID: 17097688
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid.
Masso-Welch PA; Zangani D; Ip C; Vaughan MM; Shoemaker S; Ramirez RA; Ip MM
Cancer Res; 2002 Aug; 62(15):4383-9. PubMed ID: 12154044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
